Background {#Sec1}
==========

Nearly 44 million people worldwide have Alzheimer's disease (AD) or a related dementia, with global costs of the disease estimated to be approximately \$600 billion in 2016 and steadily increasing as the population ages, making it a major public health issue \[[@CR1], [@CR2]\]. The hallmark symptoms of AD include memory impairment and cognitive decline, both of which largely drive clinical diagnosis. Existing therapies do not treat the underlying cause of the disease, and only temporarily help relieve memory and cognitive problems. There are several drugs currently under development which aim to modify the disease process; however, there still exists a lack of understanding regarding the molecular mechanisms underlying the disease, thus making it challenging to identify new targets for therapy. Accurate diagnosis of prodromal AD is essential to starting treatments at the right time, and in treating the disease more effectively \[[@CR3]\]. The identification of a robust, prodromal, and easily accessible biomarker has been of major interest in the field.

The Alzheimer's Disease Neuroimaging Initiative (ADNI) was launched in 2003 with the goal to establish an optimal panel of clinical assessments: imaging measures (MRI, PET) and biomarkers from blood and cerebrospinal fluid (CSF) to direct clinical trial design for AD drugs \[[@CR4], [@CR5]\]. We sought to use this resource to determine if epigenetic markers in PB could serve as biomarkers of AD.

Epigenetic modifications are inheritable and dynamic, and may lead to the regulation of gene expression via modifications to the cytosine residues and/or proteins associated with nucleosome assembly and function \[[@CR6]\]. Methylation of the DNA cytosine bases has been studied for several decades and studies have associated methylation at promoter regions with repression of gene expression \[[@CR7]\]. DNA methylation changes as a result of mutations in the DNA methyltransferase-1-enzyme have been shown to be associated with several neuronal diseases including hereditary sensory and autonomic neuropathy-1, in which patients display disrupted methylation patterns potentially contributing to neurodegeneration \[[@CR8]\]. De novo mutations of MeCP2, a methyl CpG-binding protein, are linked to Rett syndrome, a progressive neurodevelopmental disorder \[[@CR9]\]. Other epigenetic mechanisms link exposures during the course of life such as nutrition, chemical and emotional environments, pregnancy conditions, drug intake, and social status to long-term health of the individual \[[@CR10], [@CR11]\]. These observations and others support the significance of DNA methylation and associated machinery in the temporal control of neural stem cell differentiation, neurodevelopment, and neurodegeneration.

Several studies have observed widespread alterations in DNA cytosine methylation patterns both at the global level as well as at the individual loci in AD brains (reviewed in \[[@CR12]--[@CR15]\]). In 2014, two seminal papers identified DNA methylation patterns that characterize AD brains and correlate with progression as defined by their Braak stages \[[@CR16], [@CR17]\]. Given that observed differences in DNA methylation levels across tissues are stable in a healthy individual, and may be exploited to determine early changes associated with disease processes \[[@CR18], [@CR19]\], we sought to understand patterns of peripheral blood DNA methylation in the ADNI cohort. Our objectives from this study were to (1) generate a public resource for peripheral DNA methylation marks in a cohort of cognitively normal, MCI, and AD patients; (2) to identify cross-sectional differences in peripheral blood DNA methylation associated with mild cognitive impairment (MCI) and AD patients relative to cognitively normal controls (CN); and (3) identify novel non-invasive disease biomarkers. This information would also help identify subjects who are more susceptible to disease progression. Our goal is to gain a broader understanding of how peripheral DNA methylation differences correlate with the diagnosis of and progression of Alzheimer's disease and to enable the research and clinical community to leverage these results to assess the potential for use of methylation changes as pharmacodynamic or disease modifying biomarkers.

Results {#Sec2}
=======

Making available a robust resource for DNA methylation differences in the peripheral blood of Alzheimer's disease patients {#Sec3}
--------------------------------------------------------------------------------------------------------------------------

A total of 1920 samples from 653 individual subjects (CN, MCI, AD) were analyzed using the Illumina EPIC arrays (Table [1](#Tab1){ref-type="table"}). Two experimental factors were considered for patient selection: (1) time- our ability to capture the longitudinal aspect of the study (patients with samples at two or more visits), and (2) diagnosis and its time-varying nature (patients converting from CN to MCI, CN to AD, or MCI to AD). Details of patient selection are included in the "Methods" section. The current study focuses on differential methylation analysis of subjects based on diagnosis. One hundred and ninety-nine duplicates and a single triplicate were included amongst the samples that were run on the EPIC arrays for technical replication but are not used in the final analysis here. Table 1ADNI patient cohort selected for DNA methylation analysis and used for final analysis after normalization and quality controlStarting Patient Cohort (N=653; 1720 DNA samples)Diagnosis GroupsAge in years Mean (SD)Number of Males (%)Number APOE e4 positive (%)Cognitively Normal (n=223)76.23 (6.7)112 (50.2%)58 (26%)Mild Cognitive Impairment (n=336)72.58 (7.82)189 (56.3%)153 (46%)Alzheimer\'s Disease (n=94)77.19 (7.69)60 (63.8%)64 (68%)After Normalization , Quality Control and Removal of Replicates (total 1707)Diagnosis at 1^st^ VisitNumber at Visit 1Number at Visit 2Number at Visit 3Number at Visit 4Number at Visit 5Cognitively Normal220200162154Mild Cognitive Impairment333312235234Alzheimer's Disease945351\--

Distribution of differentially methylated positions (DMPs) is consistent across each cross-diagnosis comparison {#Sec4}
---------------------------------------------------------------------------------------------------------------

After extensive quality control evaluation to filter poor probes and low-quality samples, the data were normalized and M-values (i.e., the logit of the beta values) were used for all further analyses. We analyzed differential DNA methylation across diagnosis groups using a mixed model with a random effect to account for within-subject dependency as detailed in the methods section. This allowed us to include all available time points for all subjects. The model included covariates to adjust for age at diagnosis, sex, educational attainment, and peripheral blood cell composition, and this yielded 260, 91, and 137 DMPs, respectively, for the three clinical phenotypic comparisons: AD vs. CN, AD vs. MCI, and MCI vs. CN, with a *p* value threshold of 1 × 10^−5^ (Table S[2](#MOESM1){ref-type="media"}). The majority of the DMPs were clustered within the open seas (genomic loci that fall outside of the CpG islands), and the adjacent shores (regions 0--2 kb from CpG islands), and shelves (regions 2--4 kb from CpG islands) (Fig. [1](#Fig1){ref-type="fig"}a--c). The relative levels of enrichment of specific genomic regions (e.g., gene body, 5′-UTR) within the DMP list from three comparisons were similar and did not show significant differences (Fig. [1](#Fig1){ref-type="fig"}d). Fig. 1Distribution of cross-diagnosis differential DNA methylation marks across the genome. **a**--**c** Distribution of differential DNA methylation marks relative to the CpG island. Islands are denoted by yellow, shelves (regions 2--4 kb from CpG Islands) by purple, shores (regions 0--2 kb from CpG Islands) by blue and the open seas (genomic loci that fall outside of the islands, shelves, and shores) by orange. Percentages are calculated as percent total number of hits. **d** Distribution of differential DNA methylation marks across different genomic loci. Annotations of the locations are obtained from Illumina EPIC manifests: TSS1500 = within 1500 bp of transcription start site (TSS); TSS200 = within 200 bp of TSS

DMPs from each pairwise comparisons are enriched for brain-related pathways {#Sec5}
---------------------------------------------------------------------------

There were 42 DMPs that cleared the p-value of 1 × 10^−5^ in the AD vs CN comparison (Fig. [2](#Fig2){ref-type="fig"}a). The DMP that was most significantly associated with AD relative to CN was annotated to *FAM8A1*, which encodes a protein that is associated with endoplasmic reticulum-associated degradation of proteins with roles in Alzheimer's disease pathogenesis (Fig. [2](#Fig2){ref-type="fig"}b). Additionally, when we interrogated the genes located closest to the top DMPs using Tissue Specific Expression Analysis (TSEA), a web-based tool designed to look for tissue-specific expression patterns across 25 different tissue types via GTex Data \[[@CR20], [@CR21]\], we observed enrichment for brain-specific genes (*P*~adj~-val = 9 × 10^−4^) (Figure S[3](#MOESM1){ref-type="media"}A, Table S[3](#MOESM1){ref-type="media"}). Other tissues that showed enrichment for the AD vs. CN comparison included: pituitary (*P*~adj.~-value = 0.016) and uterus (*P*~adj.~-value = 9 × 10^−4^). We measured the correlation of observed differential DNA methylation with a cognitive score, MMSE (the mini-mental status examination) and found a significant (*p* value = 3.8 × 10^−5^) correlation of MMSE, with DNA methylation differences at this locus (Fig. [2](#Fig2){ref-type="fig"}c). We tested the enrichment of neural gene expression in parallel using gene ontology analysis, which identified neurogenesis and neuronal differentiation as some of the most highly enriched pathways in the AD vs. CN annotated DMPs (Table [2](#Tab2){ref-type="table"}). Fig. 2Comparison of DNA methylation in AD (Alzheimer's disease) vs CN (cognitively normal). **a** Manhattan plot showing the top hits in the AD vs CN comparison. The blue line indicates *p* value threshold of 1 × 10^−5^ and the red line indicates *p* value threshold of 1 × 10^−7^. **b** Distribution of unadjusted *M* values in *FAM8A1*, the top DMP across CN (green), MCI (blue), and AD (red). Violin plots outline the spread of the data. **c** Correlation of MMSE scores with differential methylation at the *FAM8A1* locusTable 2Gene ontology analysis of genes within 50 kb of differentially methylated positions from each cross-diagnosis comparisonGene Set Name\# Genes in Gene Set (K)\# Genes in overlap (k)k/KFDR q-valueCross-Diagnosis Comparison of AD vs CN at All VisitsBENPORATH_SUZ12_TARGETS1038370.03561.98E-22BENPORATH_ES_WITH_H3K27ME31118380.0342.60E-22BENPORATH_EED_TARGETS1062370.03484.29E-22**GO_NEURON_DIFFERENTIATION874290.03326.78E-17GO_NEUROGENESIS1402350.0252.00E-16**BENPORATH_PRC2_TARGETS652250.03834.04E-16GO_CELL_DEVELOPMENT1426330.02311.36E-14MIKKELSEN_NPC_HCP_WITH_H3K27ME3341180.05282.97E-14MEISSNER_BRAIN_HCP_WITH_H3K4ME3_AND_H3K27ME31069280.02628.47E-14MIKKELSEN_MEF_HCP_WITH_H3K27ME3590200.03393.87E-12Cross-Diagnosis Comparison of MCI vs CN at All Visits**GO_NEUROGENESIS1402180.01281.35E-09GO_CELL_PROJECTION1786200.01121.52E-09**MEISSNER_NPC_HCP_WITH_H3_UNMETHYLATED536120.02242.32E-09BENPORATH_SUZ12_TARGETS1038150.01457.80E-09**MEISSNER_BRAIN_HCP_WITH_H3K4ME3_AND_H3K27ME31069150.0141.15E-08**BENPORATH_ES_WITH_H3K27ME31118150.01342.08E-08GO_CELL_DEVELOPMENT1426160.01127.88E-08BENPORATH_EED_TARGETS1062140.01327.96E-08**GO_CELL_PROJECTION_PART946130.01371.50E-07**GSE40443_INDUCED_VS_TOTAL_TREG_UP20070.0353.03E-07Cross-Diagnosis Comparison of AD vs MCI at All VisitsGO_INTRINSIC_COMPONENT_OF_PLASMA_MEMBRANE1649150.00917.16E-08GO_CELL_SURFACE757100.01324.97E-07GRYDER_PAX3FOXO1_ENHANCERS_IN_TADS975110.01136.04E-07**GO_CELL_PROJECTION1786140.00781.22E-06**BIOCARTA_LAIR_PATHWAY1730.17652.91E-06GO_ALPHA_ACTININ_BINDING2130.14295.66E-06**BLALOCK_ALZHEIMERS_DISEASE_DN1237110.00895.94E-06GO_NEURON_PART1265110.00877.34E-06**GO_REGULATION_OF_TRANSPORT1804130.00727.65E-06

In a similar way, we identified differential methylation from the MCI vs CN comparison, which yielded 25 DMPs at a *p* value threshold of 1 × 10^−5^ (Fig. [3](#Fig3){ref-type="fig"}a). The DMP that had the strongest association with MCI vs CN was annotated to *CLIP4* (Fig. [3](#Fig3){ref-type="fig"}b). The clustering of the methylation signal correlates with the presence of a SNP at the CpG or within the probe that appears to differentially correlate with disease status. *CLIP4* is a member of the CAP-Gly Domain Containing Linker Protein Family, an important paralog of which, CLIP3, is associated with microtubule binding. Again, TSEA analysis identified enrichment of the brain-specific signals (*P*~adj.~-value = 0.0007). There was also a significant (*p* value = 2.0 × 10^−5^) correlation of MMSE score with DNA methylation differences at this locus (Fig. [3](#Fig3){ref-type="fig"}c). We also found neurogenesis, cell projection, and brain-specific high CpG-rich promoters as some of the most highly enriched pathways/components when the MCI vs. CN DMPs were annotated (Table [2](#Tab2){ref-type="table"}). Fig. 3Comparison of DNA methylation in MCI (Mild cognitive impairment) vs CN (cognitively normal). **a** Manhattan plot showing the top hits in the MCI vs CN comparison. The blue line indicates *p* value threshold of 1 × 10^−5^ and the red line indicates *p* value threshold of 1 × 10^−7^. **b** Distribution of unadjusted *M* values in *CLIP4*, the top DMP across CN (green), MCI (blue), and AD (red). Violin plots outline the spread of the data. **c** Correlation of MMSE scores with differential methylation at the *CLIP4* locus.

Differential methylation analysis of the AD vs MCI comparison yielded 13 DMPs that were significant (Fig. [4](#Fig4){ref-type="fig"}a). The strongest associated DMP was annotated to *NUCB2* (nucleobindin 2), a calcium ion binding protein that regulates intracellular calcium levels. Given the small number of hits, TSEA showed no enrichment of brain-specific pathways, but a slight enrichment of lung-related pathways (Figure S[3](#MOESM1){ref-type="media"}C, Table S[3](#MOESM1){ref-type="media"}). There was a significant (*p* value = 4 × 10^−4^) correlation of MMSE score with DNA methylation differences at this locus (Fig. [4](#Fig4){ref-type="fig"}c). Interestingly, parallel testing in gene ontology analysis showed enrichment of genes that are downregulated in Alzheimer's disease as well as cell projections, and neuronal pathways (Table [2](#Tab2){ref-type="table"}). In addition, *BIN1*, *BDNF*, and *APOC1* while not the top most differentially methylated hits, were among the significant DMP hits (Figure S[4](#MOESM1){ref-type="media"}A--C). Fig. 4Comparison of DNA methylation in AD (Alzheimer's disease) vs MCI (mild cognitive impairment). **a** Manhattan plot showing the top hits in the AD vs MCI comparison. The blue line indicates *p* value threshold of 1 × 10^−5^ and the red line indicates *p* value threshold of 1 × 10^−7^. **b** Distribution of unadjusted *M* values in *NUCB2*, the top DMP across CN (green), MCI (blue), and AD (red). Violin plots outline the spread of the data. **c** Correlation of MMSE scores with differential methylation at the *NUCB2* locus

Deriving genetic information from differential DNA methylation signals {#Sec6}
----------------------------------------------------------------------

Several studies have found an association of genetic variants with the DNA methylation signals at specific probes \[[@CR22], [@CR23]\]. To further evaluate the likelihood of DMPs correlating with AD, we also queried all the DMP-associated genes within the GWAS catalog for AD, (<https://ebi.ac.uk/gwas/>) which includes 72 individual GWAS studies and found overlaps between the GWAS hits and the DMPs from AD vs. CN, AD vs. MCI, and MCI vs. CN comparisons (Figure S[5](#MOESM1){ref-type="media"}A). Some of the overlaps included *BIN1* (Figure S[5](#MOESM1){ref-type="media"}C), *KCNN2* (Figure S[5](#MOESM1){ref-type="media"}B), *DIP2C* (Figure S[5](#MOESM1){ref-type="media"}C), *PAK2* (Figure S[5](#MOESM1){ref-type="media"}D), *C3orf67* (Figure S[5](#MOESM1){ref-type="media"}E), and *WNT3* (Figure S[5](#MOESM1){ref-type="media"}F). We were also able to utilize the methylation data to identify disease-specific associations with some novel SNPs previously linked to neurodevelopmental and neuropsychiatric disorders. For example, *ANK3* has been associated with mental retardation, *SLC45A1* with intellectual developmental disorder, and *CHI3L1* with schizophrenia (Table S[4](#MOESM1){ref-type="media"}), suggesting that differential methylation data may help reveal novel genetic variations that associate with AD. These associations could be interesting hypotheses requiring further testing.

Replication of differential methylation signals across multiple datasets {#Sec7}
------------------------------------------------------------------------

Finally, we queried a second dataset for differential methylation at the loci identified in our study. A comprehensive study of about 1628 samples assessed human samples across several different types of tissues, including leukocytes, brain regions, and several cancer tissues \[[@CR24]\]. Comparison of differential methylation in leukocytes from 65 healthy control subjects that were age 65 years or older with 35 AD subjects within the aforementioned study identified several DMPs. In an effort to replicate our findings from ADNI peripheral blood, we tested for overlaps across our study and the output from the above and observed overlaps across 11 CpGs (Table [3](#Tab3){ref-type="table"}). Table 3Replication of differential methylation across datasets (using Fernandez et al. Leukocyte data)ComparisonGeneDiscovery CpGDiscovery P-valueReplication CpG locusReplication P-valueAD vs CNADCYAP1cg162881253.02 × 10^-5^chr18:905,549-905,5503.78E-09EPHB3cg224627262.57 × 10^-6^chr3:184,561,230-184,561,2311.78E-05GDF10cg004148352.5 × 10^-5^chr10:47,300,094-47,300,0957.89E-04PARP1cg271138482.74 × 10^-5^chr1:226,408,700-226,408,7011.25E-01MCI vs ADDAB2IPcg204162968.69 × 10^-6^chr9:121,698,699-121,698,7004.49E-01METcg044324938.6 × 10^-5^chr7:116,672,738-116,672,7397.05E-03APOC1cg077735936.06 × 10^-5^chr19:44,914,258-44,914,2599.97E-03ITGB1cg053760346.42 × 10^-5^chr10:32,958,721-32,958,7226.20E-02MCI vs CNSOX1cg079116649.5 × 10^-6^chr13:112,066,581-112,066,5821.12E-01WNT1cg223766881.56 × 10^-5^chr12:48,972,583-48,972,5843.90E-06DAPK1cg102401273.1 × 10-5chr9:87,497,927-87,497,9288.85E-04

Discussion {#Sec8}
==========

We have successfully assayed peripheral blood samples from ADNI to investigate differential DNA methylation in mild cognitively impaired and Alzheimer's disease patients across serial visits using the Illumina EPIC chip. The success rate for the experiment was 99.7%, with only 15 samples out of the total 1920 that failed the run and/or quality control thresholds. Our work establishes the robustness of DNA methylation as a peripheral marker and demonstrates the consistency and reproducibility of its detection at \> 99% concordance across replicates.

The cross-diagnosis analysis demonstrates that a common set genomic loci in the periphery are differentially methylated in individuals with AD compared to normal healthy individuals. Several of these differential methylation marks were also replicated in a second peripheral DNA methylation dataset. Additionally, PB DNA methylation differences were found to be enriched near or within genes previously shown to associate with brain-associated pathways. The differential methylation at these sites correlates with cognitive scores, suggesting a relationship between the differential methylation with endophenotypes of disease progression.

When assessing the overlap in DNA methylation patterns in the periphery and the brain, previous studies have demonstrated that genome-wide DNA methylation profiles are specific to the tissue being studie d\[[@CR16], [@CR25]--[@CR27]\]. These studies have suggested that even though many of the DMPs were associated with differentially expressed transcripts, blood-based epigenome-wide association studies from methylation arrays may not correlate with disease etiology \[[@CR25]\]. In contrast, some other studies have shown conservation of DNA methylation patterns across blood and brain \[[@CR18], [@CR28], [@CR29]\], specifically at promoter regions \[[@CR18]\], or via co-expression modules that correlate the brain and the blood to age \[[@CR29]\]. Our study picks up some signals in the periphery that are enriched for brain-specific loci; however, this warrants additional studies to detect the blood-brain overlap in DNA methylation. Interestingly, a recent article based on the ENIGMA studies (MRI readouts from 3337 individuals) demonstrated an association of blood DNA methylation with volumes of the hippocampus, thalamus, and nucleus accumbens (NAcc) \[[@CR30]\].

The ADNI participant cohort has previously been used to identify novel biomarkers of disease development and progression \[[@CR31]--[@CR33]\], and is uniquely suited to measure and validate these changes. Ongoing work includes the integration of the methylation data with the rich phenotypic (e.g., cognitive, memory, neuroimaging) and multi-omic data (e.g., genotypic, expression, metabolomics) from the ADNI dataset. This will allow for the use of peripheral DNA methylation marks to function as a dynamic biomarker of disease progression and response to drug treatment.

Peripheral differential methylation has been used as a biomarker of disease occurrence and progression across several therapeutic areas including autoimmune diseases, cancers, and heart disease \[[@CR34]--[@CR36]\]. Previous methylation studies undertaken with PB or peripheral blood mononuclear cell (PBMC) samples mostly provided a snapshot of DNA methylation changes in the periphery that associated with disease status. A recent study described the identification of PB DNA methylation changes that associated with normal brain aging and cognitive decline in the Whitehall imaging study \[[@CR37]\]. For most biomarkers being studied, longitudinal measures appear to more sensitively predict cognitive decline \[[@CR38], [@CR39]\]. Our study design includes longitudinal DNA samples and further analysis will measure dynamic changes in DNA methylation that associate with disease progression. The potential value of DMPs as a surrogate for disease is critically important and can change our approach to clinical studies. Presentation of these results gives the field an opportunity to further investigate and validate the DMPs as surrogates of disease.

Methods {#Sec9}
=======

Subjects {#Sec10}
--------

ADNI is a longitudinal study with approximately 50 sites across the USA and Canada that was launched in 2003 with a major goal being to track the AD progression using clinical and cognitive tests, magnetic resonance imaging (MRI), fludeoxyglucose PET, amyloid PET, cerebrospinal fluid, and blood biomarkers. The institutional review boards of all participating sites reviewed and approved the data collection protocol provided by ADNI. Clinical descriptions of the ADNI cohort have been published \[[@CR40]\]. Six hundred and fifty-three individuals from two phases of ADNI (ADNI2 and ADNIGO) were selected for performing DNA methylation analysis (Table [1](#Tab1){ref-type="table"}) based on the completeness of their other datasets (genotyping \[APOE, TOMM40\], genome wide array, whole genome sequencing, proteomic and imaging data). A total of 1720 samples were obtained, and randomized using a modified incomplete balanced block design, whereby all samples from a subject were on the same chip, with remaining chip space occupied by age-matched samples from a subject of the opposite sex with a different diagnosis. Unused chip space was leveraged for technical reproducibility assessment via replicated DNA samples. A total of 200 samples were replicated across all the chips (Figure S[1](#MOESM1){ref-type="media"}), for a total 1920 samples processed. Among these replicates, we found consistent DNA methylation signals both within plates and across plates. The correlation coefficient was 99.63% when the replicates were on the same plate with the same scan date, and 99.25% when the replicates were on different plates with different scan dates (Table S[1](#MOESM1){ref-type="media"}).

EPIC chip runs {#Sec11}
--------------

Illumina EPIC chips (Illumina, Inc., San Diego, CA, USA) were used to assay for DNA methylation levels according to published Illumina protocols. Genomic DNA samples obtained from NCRAD (National Centralized Repository for Alzheimer\'s Disease and Related Dementias) were bisulfite converted using the EZ-DNA Methylation kits (Zymo Research, Irvine, CA, USA) and subsequently analyzed using the Illumina Infinium HD methylation protocol on the HiScan (Illumina).

Normalization and quality control methods {#Sec12}
-----------------------------------------

The derived beta values were transformed to *M* values and used for further analysis. The scan output was run through Genome Studio software (Illumina) to assay for initial QC metrics. One sample out of the total 1920 failed the run and had no CpG calls. The remaining samples had an average of CpG call of 864,640. Four additional samples failed quality control since ≥ 1% of CpG sites had a detection *p* value \> 0.05 using watermelon \[[@CR41]\]. All 1915 samples were normalized using the dasen method in wateRmelon \[[@CR41]\].

Sample identity checks {#Sec13}
----------------------

Sample sex was examined by computing the ratio of the X and Y probe intensities for each subject compared to their expected value, with \> 99% of subjects mapping to the given sex (Figure S[2](#MOESM1){ref-type="media"}A). The following R packages were used to check sample quality and possible sample mix-ups via sex-mismatches: Cham p\[[@CR42]\], minfin \[[@CR43]\], methylumi \[[@CR44]\], and watermelon \[[@CR41]\]. Additionally, we used the 59 tracking cpgs on the Illumina EPIC chips which are proxies for SNP fingerprinting (i.e., probe contains C allele that is a common variant), and compared those to the ADNI GWAS genotyping array data at the same positions (Figure S[2](#MOESM1){ref-type="media"}B) using a clustering algorithm (*k* = 3) to convert cpg signal to genotype based on Hardy-Weinberg equilibrium. The GWAS data were procured from LONI (<http://www.loni.usc.edu/>). After normalization, quality control, and removal of duplicates, 1707 samples were analyzed for differences in DNA methylation.

Statistical analysis {#Sec14}
--------------------

Since we wanted to include all the samples available for each subject in our initial analysis to compare across diagnoses, we fitted a mixed effects model on the *M* values to account for repeated measures of DNA methylation for the patients. This was done using the limma package \[[@CR45]--[@CR48]\] using dupcor estimated at the subject-level. We evaluated the association between DNA methylation level and diagnosis in multivariate models adjusted for age, sex, education, cell composition changes, and DNA storage/source in the model as shown in supplementary material. As it is known that peripheral blood cell composition can substantially affect methylation differences \[[@CR41]\] between individuals, differential methylation analysis requires that any change in cell composition be adjusted for. Cell composition estimates were obtained using estimateCellCounts \[[@CR43]\] at default settings such that estimates are made for CD8T, CD4T, NK, Bcell, Mono, and Gran. Because they lie in \[0,1\] and are constrained to sum to 1 within a sample, including all 6 values as covariates would induce multicollinearity. Therefore, only 5 cell type values are used as covariates. Furthermore, the difference in the storage of the sample used for DNA isolation (whole blood vs. buffy coat) had an impact on the cell composition, prompting its use as an additional covariate, as detailed in Supplementary Material.

Functional analysis of top differentially methylated positions (DMPs) {#Sec15}
---------------------------------------------------------------------

Tissue specific analysis of differentially methylated marks was performed using Tissue Specific Expression Analysis (TSEA) at <http://genetics.wustl.edu/jdlab/tsea/> \[[@CR20]\]. Gene ontology analysis was performed using the molecular signature database (MSigDB) at <http://software.broadinstitute.org/gsea/index.jsp> \[[@CR49], [@CR50]\]. Curated gene sets (Biocarta, KEGG, and Reactome), Gene ontology gene sets (GO biological process, GO cellular component, and GO molecular function), and Immunologic signatures were included in the pathway analysis, and an FDR *q* value of 0.05 was set as the threshold.

Additional details regarding statistical analyses are included in supplemental information.

Supplementary information
=========================

 {#Sec16}

**Additional file 1: Fig. S1**. Plate layout after randomization. **Fig. S2**. Quality Control and Confirmation of Sample Identity. **Fig. S3**. Tissue-Specific Expression Analysis identifies Brain-Specific Enrichment. **Fig. S4**. DNA Methylation Differences in Genes Previously Associated with AD Pathogenesis. **Fig. S5**. GWAS Hits Show Concordant DNA Methylation differences. **Table S1**. Correlation of Replicate Samples (200 total technical replicates) within non-normalized data. **Table S2**. Table of all DMPs. **Table S3**. Interpretation of TSEA results.
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